REPLIMUNE GROUP, INC. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
REPLIMUNE GROUP, INC. (REPL) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $19.00 million as of 2026-03-31, per its 10-K filed 2026-06-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-06-29
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $19.00M.
- 2025-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $23.90M.
- 2024-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $33.00M.
- 2023-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $34.80M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2026-03-31 | $19.00M 10-K · filed 2026-06-29 |
| 2025-03-31 | $23.90M 10-K · filed 2025-05-22 |
| 2024-03-31 | $33.00M 10-K · filed 2024-05-16 |
| 2023-03-31 | $34.80M 10-K · filed 2023-05-18 |
| 2022-03-31 | $37.90M 10-K · filed 2022-05-19 |
| 2021-03-31 | $35.60M 10-K · filed 2021-05-20 |
| 2020-03-31 | $18.70M 10-K · filed 2021-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |